Falsified Medical Product Alert N°3/2025
IMFINZI (durvalumab) injection 500mg/10ml: falsified product alert
WHO issued this alert on three falsified lots of IMFINZI, a lung cancer medicine, reported to WHO in March 2025. WHO said the products deliberately misrepresent their identity, composition and source. It follows Alert N°5/2024 on another falsified IMFINZI batch.1,2
- Issued
- 14 May 2025
- Issued by
- World Health Organization
- Name stated on packaging
- Packaging bears the IMFINZI brand of AstraZeneca. Lots BAZR and BBEG are genuine lot numbers assigned to India and Egypt respectively, reproduced on falsified packs.
- Genuine manufacturer's statement
- WHO said AstraZeneca identified multiple visual discrepancies and confirmed the products are falsified. Lot AVZT is not recognised by the genuine manufacturer.
- Countries where detected
- Iran, Türkiye
Batches named in the alert
BAZR (stated expiry 03-2025, Iran), BBEG (stated expiry 12-2025, Iran), AVZT (stated expiry 12-2026, Türkiye)
Advice as stated
Do not use the listed products. Obtain medicines only from authorised or licensed suppliers. Report adverse events, lack of effect or suspected falsification to the national regulatory authority or pharmacovigilance centre.
Names printed on falsified products are not evidence that the named company made them. Where WHO or a regulator reports the genuine manufacturer's statement, it is shown.
Sources
- World Health Organization, Medical Product Alert N°3/2025: Falsified IMFINZI (durvalumab) injection 500mg/10ml (14 May 2025)
- World Health Organization, Medical Product Alert N°3/2025: annex (PDF) (14 May 2025)